Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.41 |
| ▸ | LTA4H | P09960 | 2/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1720258 | 0.82 | LTA4H (0.40) | HTTALDH1A1SMN1; SMN2LTA4HMAPT | |
| SCHEMBL1718985 | 0.77 | MAPT (0.53) | LMNAHTTALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL9988598 | 0.75 | LMNA (0.56) | LMNAHTTALDH1A1TDP1CYP19A1 | |
| SCHEMBL6031667 | 0.74 | CA1 (0.33) | ALDH1A1LTA4HMAPT | |
| SCHEMBL6029387 | 0.74 | MAPT (0.42) | LMNAHTTALDH1A1SMN1; SMN2LTA4H | |
| SCHEMBL9988640 | 0.71 | LMNA (0.51) | LMNAHTTALDH1A1TDP1CYP19A1 | |
| SCHEMBL676142 | 0.71 | LMNA (0.82) | LMNAHTTALDH1A1TDP1CYP19A1 | |
| SCHEMBL30535283 | 0.71 | LMNA (0.82) | LMNAHTTALDH1A1TDP1CYP19A1 | |
| SCHEMBL177519 | 0.71 | LMNA (0.80) | LMNAHTTALDH1A1TDP1SMN1; SMN2 | |
| SCHEMBL30098501 | 0.71 | LMNA (0.80) | LMNAHTTALDH1A1TDP1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1503986-B1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2015-09-30 | — | — | EP | claimed |
| US-7605164-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2009-10-20 | — | — | US | claimed |
| US-20060173024-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-08-03 | — | — | US | claimed |
| US-7053094-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-05-30 | — | — | US | claimed |
| EP-1503986-A4 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2005-11-30 | — | — | EP | claimed |
| US-20050148638-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | US | claimed |
| US-6908923-B2 | N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide | CYTOKINETICS, INC. (US) | 2005-06-21 | — | — | US | claimed |
| EP-1503986-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | claimed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | claimed |
| WO-2003059258-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | claimed |
| EP-1503986-B1 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| US-7605164-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2009-10-20 | — | — | US | disclosed |
| US-20060173024-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-08-03 | — | — | US | disclosed |
| US-7053094-B2 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1503986-A4 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS INC (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20050148638-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INC. (US) | 2005-07-07 | — | — | US | disclosed |
| US-6908923-B2 | N-(3-oxy-5-functionalphenyl)(hetero)arylcarboxamide derivatives, e.g., 4-fluoro-N-(3-(pyridin-3-yloxy)-phenyl)-benzamide | CYTOKINETICS, INC. (US) | 2005-06-21 | — | — | US | disclosed |
| EP-1503986-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | Cytokinetics, Inc. (US) | 2005-02-09 | — | — | EP | disclosed |
| US-20030158233-A1 | Compositions and methods for treating heart failure | CYTOKINETICS, INCORPORATED | 2003-08-21 | — | — | US | disclosed |
| WO-2003059258-A2 | COMPOSITIONS AND METHODS FOR TREATING HEART FAILURE | CYTOKINETICS, INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030158233-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | LMNA 228/4885HTT 3632/4885ALDH1A1 3435/4885 |
| US-20060173024-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | LMNA 228/4885HTT 3632/4885ALDH1A1 3435/4885 |
| US-20050148638-A1 | Compositions and methods for treating heart failure | MYH2, TNNI3, MYLK2 | LMNA 228/4885HTT 3632/4885ALDH1A1 3435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.